Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Autonomix Medical, Inc. (AMIX)

Autonomix Medical stockholders approve 2023 Plan increase and reverse split authority

Neutral Impact 3 of 5 shareholder Written later

At its October 29, 2026 annual meeting, Autonomix Medical stockholders approved an increase of 750,000 shares under the 2023 Stock Plan and authorized the board to seek a reverse stock split of between 1-for-2 and 1-for-25. All six director nominees were elected, and Forvis Mazars, LLP was ratified as the independent auditor for the year ending March 31, 2027. The votes give the board flexibility on share count and equity awards, but the filing does not say whether a reverse split will be pursued.

Key points

  • Annual meeting held October 29, 2026; 905,610 shares voted, about 46% of 1,959,938 shares outstanding as of the September 8, 2026 record date.
  • 2023 Stock Plan amended to add 750,000 shares; total issuable under the plan is 750,353 shares.
  • Reverse split proposal approved with 775,257 votes for and 110,036 against, authority valid until the one-year anniversary of the meeting.
  • Plan amendment approved with 225,651 votes for and 39,672 against.

The filing

CompanyAutonomix Medical, Inc. (AMIX)
Form8-K, current report
Filed with the SECNov 3, 2026, 5:00 PM ET
Accession number0001437749-26-034696

Items reported: 5.02 Director / Officer Change5.07 Shareholder Vote Results

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 03, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.